EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies

Umut Dişel iD, Shumei Kato, Aditya Shreenivas, Ayca Ersen Danyeli, Manmeet S Ahluwalia, Razelle Kurzrock

Journal of Immunotherapy and Precision Oncology · 16.03.2026 · 9 (1) · 25-31

DOI: 10.36401/jipo-25-34 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Immunotherapy and Precision Oncology, erschienen am 16.03.2026. Verfasst von Umut Dişel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Acibadem Adana Hospital, Adana, Turkey. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High-grade gliomas are associated with dismal outcomes and have devastating neurologic sequelae. Standard-of-care surgery, radiation, and temozolomide yield a median survival of 14–16 months in patients with glioblastoma (GBM).

Methods

We report four patients with high-grade glioma (two with GBM; one initially diagnosed with GBM, now classified as World Health Organization grade 4 IDH1- mutant astrocytoma; and one with oligosarcoma [grade 4]). Tumor next-generation sequencing (NGS) was performed for all four patients, and they were treated based on their biomarkers.

Results

NGS yielded actionable alterations targeted after conventional surgery/chemoradiation therapy: imatinib (for KIT and PDGRA amplification) and bevacizumab (for KDR [ VEGFR2 ] amplification); everolimus (mTOR inhibitor for TSC2 and PTEN loss-of-function alterations); and ivosidenib (IDH1 inhibitor for IDH1 mutations in two cases, including the oligosarcoma). Three patients remain in radiographic and clinical remission at 39+, 48, and 52+ months; the patient with oligosarcoma showed clinical and imaging response lasting 8 months.

Conclusions

Our exceptional responders with high-grade gliomas suggest that biomarker-matched targeted therapy can benefit select patients with high-grade glioma and warrants prospective clinical trials.

Schlagwörter

Stichwörter der Autor:innen

exceptional respondershigh-grade gliomaprecision oncologytargeted therapy

Autor:innen und Institutionen

  • Department of Medical Oncology, Acibadem Adana Hospital, Adana, Turkey.
  • Center for Personalized Cancer Therapy, Moores Cancer Center, UCSD, San Diego, CA, USA.
  • City of Hope, Duarte, CA, USA.
  • Department of Pathology Acibadem Altunizade Hospital, Istanbul, Turkey.
  • Division of Neuro-Oncology, Miami Cancer Institute, Baptist Health South Florida, FL, USA.
  • Clinical Cancer Center - Froedtert Hospital, Medical College of Wisconsin, Milwaukee, WI, USA.

ORCID-Profile: Umut Dişel

Zitieren

APA

Dişel, U., Kato, S., Shreenivas, A., Danyeli, A. E., Ahluwalia, M. S., & Kurzrock, R. (2026). Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies. Journal of Immunotherapy and Precision Oncology, 9(1), 25-31. https://doi.org/10.36401/jipo-25-34

Vancouver

Dişel U, Kato S, Shreenivas A, Danyeli AE, Ahluwalia MS, Kurzrock R. Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies. Journal of Immunotherapy and Precision Oncology. 2026;9(1):25-31. doi:10.36401/jipo-25-34

BibTeX
@article{Diel2026,
  author = {Dişel, Umut and Kato, Shumei and Shreenivas, Aditya and Danyeli, Ayca Ersen and Ahluwalia, Manmeet S and Kurzrock, Razelle},
  title = {Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies},
  journal = {Journal of Immunotherapy and Precision Oncology},
  year = {2026},
  volume = {9},
  number = {1},
  pages = {25--31},
  doi = {10.36401/jipo-25-34}
}
Kostenlos starten →